Principal Financial Group Inc. grew its holdings in Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) by 3.1% in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 15,699 shares of the biopharmaceutical company’s stock after acquiring an additional 477 shares during the period. Principal Financial Group Inc. owned 0.06% of Intercept Pharmaceuticals worth $1,901,000 as of its most recent SEC filing.

Other hedge funds have also bought and sold shares of the company. Oppenheimer & Co. Inc. grew its position in Intercept Pharmaceuticals by 9.0% in the first quarter. Oppenheimer & Co. Inc. now owns 2,152 shares of the biopharmaceutical company’s stock worth $244,000 after acquiring an additional 178 shares in the last quarter. Geode Capital Management LLC grew its position in Intercept Pharmaceuticals by 12.8% in the first quarter. Geode Capital Management LLC now owns 144,130 shares of the biopharmaceutical company’s stock worth $16,301,000 after acquiring an additional 16,392 shares in the last quarter. Bank of New York Mellon Corp grew its position in Intercept Pharmaceuticals by 10.2% in the first quarter. Bank of New York Mellon Corp now owns 68,302 shares of the biopharmaceutical company’s stock worth $7,725,000 after acquiring an additional 6,312 shares in the last quarter. Point72 Asset Management L.P. grew its position in Intercept Pharmaceuticals by 13.1% in the first quarter. Point72 Asset Management L.P. now owns 220,600 shares of the biopharmaceutical company’s stock worth $24,950,000 after acquiring an additional 25,500 shares in the last quarter. Finally, Parametric Portfolio Associates LLC grew its position in Intercept Pharmaceuticals by 74.2% in the first quarter. Parametric Portfolio Associates LLC now owns 28,007 shares of the biopharmaceutical company’s stock worth $3,168,000 after acquiring an additional 11,933 shares in the last quarter. 82.19% of the stock is owned by institutional investors.

In other Intercept Pharmaceuticals news, Director Daniel G. Welch sold 217 shares of Intercept Pharmaceuticals stock in a transaction on Thursday, July 20th. The shares were sold at an average price of $126.76, for a total transaction of $27,506.92. Following the completion of the transaction, the director now directly owns 3,710 shares of the company’s stock, valued at $470,279.60. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Lisa Bright sold 253 shares of Intercept Pharmaceuticals stock in a transaction on Friday, August 25th. The stock was sold at an average price of $111.31, for a total transaction of $28,161.43. Following the transaction, the insider now directly owns 23,324 shares of the company’s stock, valued at $2,596,194.44. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 6,920 shares of company stock valued at $672,822. Company insiders own 9.20% of the company’s stock.

Intercept Pharmaceuticals, Inc. (NASDAQ ICPT) opened at 69.915 on Friday. Intercept Pharmaceuticals, Inc. has a 1-year low of $54.98 and a 1-year high of $156.65. The firm’s market capitalization is $1.75 billion. The company’s 50-day moving average is $92.20 and its 200 day moving average is $110.42.

Intercept Pharmaceuticals (NASDAQ:ICPT) last released its quarterly earnings data on Monday, July 31st. The biopharmaceutical company reported ($3.46) EPS for the quarter, topping the Zacks’ consensus estimate of ($3.62) by $0.16. Intercept Pharmaceuticals had a negative net margin of 543.35% and a negative return on equity of 135.24%. The firm had revenue of $30.89 million during the quarter, compared to analysts’ expectations of $27.50 million. During the same period in the previous year, the business posted ($3.14) earnings per share. The company’s revenue for the quarter was up 459.6% compared to the same quarter last year. On average, equities analysts expect that Intercept Pharmaceuticals, Inc. will post ($13.98) EPS for the current fiscal year.

Several research firms have commented on ICPT. JMP Securities downgraded shares of Intercept Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research report on Wednesday. Royal Bank Of Canada upped their price objective on shares of Intercept Pharmaceuticals from $200.00 to $244.00 and gave the stock an “outperform” rating in a report on Tuesday, September 26th. Wedbush reaffirmed an “outperform” rating and set a $253.00 price objective on shares of Intercept Pharmaceuticals in a report on Friday, August 25th. Needham & Company LLC reaffirmed a “hold” rating on shares of Intercept Pharmaceuticals in a report on Tuesday, September 26th. Finally, Cantor Fitzgerald reaffirmed an “underweight” rating and set a $69.00 price objective (up from $60.00) on shares of Intercept Pharmaceuticals in a report on Monday, July 31st. Three analysts have rated the stock with a sell rating, ten have assigned a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus price target of $157.60.

WARNING: “Principal Financial Group Inc. Acquires 477 Shares of Intercept Pharmaceuticals, Inc. (ICPT)” was published by Watch List News and is the property of of Watch List News. If you are reading this piece on another site, it was stolen and republished in violation of United States & international trademark & copyright legislation. The correct version of this piece can be accessed at https://www.watchlistnews.com/principal-financial-group-inc-acquires-477-shares-of-intercept-pharmaceuticals-inc-icpt/1616844.html.

About Intercept Pharmaceuticals

Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.

Want to see what other hedge funds are holding ICPT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT).

Institutional Ownership by Quarter for Intercept Pharmaceuticals (NASDAQ:ICPT)

Receive News & Ratings for Intercept Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.